Insider Trading Activity NovoCure Ltd. (NASDAQ:NVCR) – COO Sold 27,500 shares of Stock

Insider Trading Activity For NovoCure Ltd. (NASDAQ:NVCR)

Michael J Ambrogi , COO of NovoCure Ltd. (NASDAQ:NVCR) reportedly Sold 27,500 shares of the company’s stock at an average price of 8.27 for a total transaction amount of $227,425.00 SEC Form

Insider Trading History For NovoCure Ltd. (NASDAQ:NVCR)

On 3/3/2016 Robert J Mylod Jr, Director, bought 20,000 with an average share price of $15.78 per share and the total transaction amounting to $315,600.00.

On 3/3/2016 Asaf Danziger, CEO, bought 10,000 with an average share price of $15.00 per share and the total transaction amounting to $150,000.00.

On 6/8/2016 Michael J Ambrogi, COO, sold 20,000 with an average share price of $12.24 per share and the total transaction amounting to $244,800.00.

On 8/5/2016 Gert L Perlhagen, Director, sold 676,576 with an average share price of $1.85 per share and the total transaction amounting to $1,251,665.60.

On 12/6/2016 Michael J Ambrogi, COO, sold 10,000 with an average share price of $8.24 per share and the total transaction amounting to $82,400.00.

On 12/8/2016 Michael J Ambrogi, COO, sold 10,000 with an average share price of $8.30 per share and the total transaction amounting to $83,000.00.

On 12/12/2016 Michael J Ambrogi, COO, sold 15,000 with an average share price of $9.01 per share and the total transaction amounting to $135,150.00.

Analyst Ratings For NovoCure Ltd. (NASDAQ:NVCR)
These are 1 Sell Rating, 1 Hold Rating, 3 Buy RatingsThe current consensus rating for NovoCure Ltd. (NASDAQ:NVCR) is Hold (Score: 2.40) with a consensus target price of $18.60 , a potential (128.22% upside)

Analyst Ratings History For NovoCure Ltd. (NASDAQ:NVCR)

• On 11/12/2015 Evercore ISI Initiated Coverage of rating Buy with a price target of $29.00
• On 7/29/2016 Barclays PLC Lower Price Target of rating Underweight with a price target of $12.00 to $9.00
• On 7/29/2016 Deutsche Bank AG Lower Price Target of rating Hold with a price target of $28.00 to $16.00
• On 7/29/2016 JMP Securities Lower Price Target of rating Market Outperform with a price target of $43.00 to $34.00
• On 11/2/2016 JPMorgan Chase & Co. Set Price Target of rating Buy with a price target of $14.00
• On 12/21/2016 Wedbush Reiterated Rating Outperform with a price target of $20.00

About NovoCure Ltd. (NASDAQ:NVCR)
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death. A TTFields delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories. The electric fields are delivered through the non-invasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The therapy is designed to be delivered throughout the day and night. The Company has performed various pre-clinical research on TTFields and their effects in multiple solid tumor cancers.

Recent Trading Activity for NovoCure Ltd. (NASDAQ:NVCR)
Shares of NovoCure Ltd. closed the previous trading session at 8.15 0.00 0.00% with 158,541 shares trading hands.